NeoStem Investor Presentation
February 10, 2015
NeoStem Publishes Investor Presentation
Updates Project Time Lines
NeoStem Update at a Glance
NeoStem has further expanded and improved its highly experienced management and scientific team and has continued the development of a robust, diversified and balanced pipeline based on proprietary technologies targeting large global markets with critical unmet medical needs. The NeoStem Immunotherapy platform is applicable across multiple solid tumors with for Orphan Drug designations and an SPA for phase 3 study in metastatic melanoma on a Fast Track. The Cell therapy platform applicable in multiple cardiovascular indications with ongoing Phase 2 study for acute myocardial infarction has produced compelling interim results. Its Immunomodulation therapy platform targeting autoimmune disorders is currenlty in a FDA approved phase 2 study in adolescents with type I diabetes. NeoStem has established bicoastal proven capabilities innovating discovery, development, manufacturing and delivery of cell-based therapies.
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell based personalized medicine therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The combination of a rich therapeutics pipeline and externally recognized in-house manufacturing expertise has created an organization with unique capabilities for cost effective and accelerated product development. www.neostem.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, the Company’s ability to develop and grow its business, the successful development of cellular therapies with respect to the Company’s research and development and clinical evaluation efforts in connection with the Company’s Targeted Immunotherapy Program, Ischemic Repair Program , Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company’s contract development and manufacturing business as well as its efforts to expand its capabilities into the cell therapy tools market. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 13, 2014, the Company’s Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.
Note: We have initiated coverage on NeoStem (NASDAQ(NBS), a leading edge cell therapy bio-tech company. We have taken a position in the stock for the SWI services and portfolio. In our opinion the stock is currently dramatically undervalued. Please go to www.stockwatchindex.com/stock-watch-index/neostem for more detail.